Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.66 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | MDM4 | O15151 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27910970 | 1.00 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL14472130 | 1.00 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL14472192 | 1.00 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL18220518 | 1.00 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL43741 | 0.99 | HDAC1 (0.64) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL42986 | 0.99 | HDAC1 (0.64) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL26114055 | 0.93 | CNR1 (0.67) | HDAC1HDAC6GRIA1 | |
| SCHEMBL31370880 | 0.93 | CNR1 (0.67) | HDAC1HDAC6GRIA1 | |
| SCHEMBL6651343 | 0.90 | ITGB3 (0.58) | HDAC1HDAC6GRIA1 | |
| SCHEMBL6651722 | 0.90 | ITGB3 (0.58) | HDAC1HDAC6GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815944-B2 | Pharmaceutical composition with gelling properties containing a tyrosine derivative | ETHYPHARM (FR) | 2014-08-26 | — | — | US | claimed |
| EP-2254550-B1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM SA (FR) | 2013-01-09 | — | — | EP | claimed |
| US-20110207813-A1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM (FR) | 2011-08-25 | — | — | US | claimed |
| US-8815944-B2 | Pharmaceutical composition with gelling properties containing a tyrosine derivative | ETHYPHARM (FR) | 2014-08-26 | — | — | US | disclosed |
| EP-2254550-B1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM SA (FR) | 2013-01-09 | — | — | EP | disclosed |
| US-20110207813-A1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM (FR) | 2011-08-25 | — | — | US | disclosed |
| EP-2254550-A1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009095485-A1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | ETHYPHARM (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207813-A1 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE | TH, LYN, TYRO3 | HDAC1 4657/4885HDAC6 4278/4885GRIA1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.